Articles tagged with Multiple Sclerosis
Cognitive dysfunction is a common symptom of multiple sclerosis, affecting two-thirds of patients. Researchers recommend cognitive rehabilitation and exercise training as promising strategies for treating cognitive deficits in MS.
A randomized clinical trial investigated treating patients with relapsing multiple sclerosis using a therapeutic hookworm infection, comparing it to placebo. The study aimed to determine if gut worms could induce immune responses that protect against multiple sclerosis.
A case series of five MS patients with favorable outcomes after developing COVID-19 while taking teriflunomide reveals potential benefits of the drug in preventing excessive immune responses. The study suggests that teriflunomide may not need to be discontinued in patients with MS who develop an active COVID-19 infection.
A review published in Neurology clarifies the different courses of multiple sclerosis (MS) and disease activity, aiming to improve patient care and clinical trial outcomes. The experts define four subtypes: clinically isolated syndrome, relapsing remitting MS, secondary progressive MS, and primary progressive MS.
A Cleveland Clinic-led research team will study the central vein sign as a reliable diagnostic marker for MS, aiming to improve accuracy and simplify clinical decision-making. The prospective study will enroll 400 patients at 11 centers in North America.
Researchers reprogrammed T-cells to recognize proteins as part of the body, preventing autoimmune diseases like multiple sclerosis. The study's findings have important implications for treating autoimmune conditions and may lead to advances in overcoming autoimmunity.
Two plasma and 10 cerebrospinal fluid biomarkers were identified to aid in early detection of MS with high sensitivity and specificity. These biomarkers may help monitor treatment response and disease progression.
A new study has found that people living in urban areas have a 29% higher risk of developing multiple sclerosis (MS) compared to those living in rural areas. The research also suggests that air pollution, specifically particulate matter (PM), may be a contributing factor to the development of MS.
A blood test detecting neurofilament light chain can predict which people with multiple sclerosis will experience worsening symptoms and disability over the next year. The study found that individuals with high levels of this biomarker were more likely to develop significant disability and secondary progressive MS.
A new animal study demonstrates that transplanted human glial cells can repair damage and restore function in models of multiple sclerosis. The findings have significant therapeutic implications and represent a proof-of-concept for clinical trials.
Researchers at CU School of Medicine have discovered that precise motor learning stimulates cellular processes to improve recovery after nerve cell damage. The study found that mature oligodendrocytes can contribute to repairing the nervous system by generating new myelin sheaths.
A new study found that mindfulness training can help multiple sclerosis patients regulate their negative emotions and improve their processing speed. The four-week program showed benefits over adaptive cognitive training and a waitlist control group.
Scientists discovered that patients with certain inflammatory demyelinating diseases have auto-immune antibodies against myelin oligodendrocyte glycoprotein (MOG), which is thought to be important in maintaining the myelin sheath's structural integrity. This finding suggests that therapeutic strategies need to be individualized for pat...
Researchers found activated T cells in brain tissue of MS patients, indicating local inflammation is driving the disease. This discovery supports the idea that white blood cells on the outside of the brain no longer influence the disease in advanced stages.
Dr Ian Duncan has made groundbreaking research on how myelin is damaged in multiple sclerosis and how it may be repaired. His work focuses on transplanting myelinating cells to promote function in people with MS.
A new diagnostic strategy has been developed by Brazilian researchers to detect biomarkers of early-stage multiple sclerosis. The method uses a nanobiosensor that can accurately identify specific antibodies in cerebrospinal fluid and blood serum, allowing for early diagnosis and treatment.
Researchers have identified a promising new target for multiple sclerosis therapy by focusing on monocytes rather than T and B cells. By targeting the Cxcl10+ monocyte subset, disease symptoms in mice were significantly improved, suggesting potential preventive measures against MS side effects.
Scientists have created a comprehensive atlas of toxic immune cells that damage the brain, revealing a potential new drug target for multiple sclerosis and possibly other neurodegenerative diseases. The 'atlas' was generated using a novel method called Tox-seq, which links gene expression to function in single cells.
Researchers found that ursolic acid promotes myelin repair in the central nervous system, even in chronic autoimmune disorders like multiple sclerosis. The study suggests a potential dual effect of ursolic acid in treating MS through both immunomodulation and direct remyelination.
Researchers discover ursolic acid reduces further damage to neurons and helps rebuild protective sheaths in MS, reversing damage. The compound suppresses harmful immune cells while activating precursor cells to produce myelin-sheath-making cells.
A Drexel University study found that using broad diagnostic terms like 'autoimmune disease' alongside narrow ones helps patients communicate their experiences. This broad category simplifies explanation to family, friends, and clinicians, even with changing diagnoses.
Researchers found that propionic acid reduced relapse rates and disability progression in MS patients, with initial MRI studies suggesting reduced brain atrophy. The gut microbiome plays a crucial role in immune regulation, and altering its composition may lead to innovative dietary measures to complement existing therapies.
A virtual reality test has shown promise in detecting balance problems in people with multiple sclerosis (MS), which can lead to falls and related injuries. The test uses a VR system to simulate falling while walking, triggering corrective reactions that can be measured as changes in gait and foot placement.
The study found improvements in brain metabolism and self-reported cognitive function improvements in patients with multiple sclerosis. N-acetylcysteine administration increased cerebral glucose metabolism and enabled neurons to recover some of their metabolic function.
A new multi-sensor tool tracks subtle changes in multiple sclerosis (MS) patients, allowing for more frequent and quick assessments of disease status and progression. The device, which takes less than five minutes to use, uses a combination of sensors to capture MS-related disability and advancement.
A pilot study found that the Spanish adaptation of the modified Story Memory Technique improved learning and life satisfaction in Mexicans with multiple sclerosis. The intervention, which teaches imagery and context to facilitate learning, may be an effective rehabilitative tool for Spanish-speaking populations with MS.
Scientists have made an important discovery that could lead to more effective treatments for people living with multiple sclerosis (MS). The study found that drugs targeting the IL-17 molecule may not need to get across the blood-brain-barrier to be effective in treating MS.
Researchers found that significantly reducing dietary methionine slows the progression of inflammatory and autoimmune disorders like multiple sclerosis. Methionine fuels T cells, which can cause inflammation and damage if it lingers.
A new drug called Myeliviz has been approved for its first human trials to aid multiple sclerosis (MS) diagnoses. The drug targets and binds to myelin, allowing for its imaging by a PET scanner, potentially providing earlier and more accurate diagnoses.
A new technique reveals that myelin produces multiple waves of electrical potentials traveling at high speeds, contradicting earlier assumptions. This discovery has significant implications for understanding demyelinating diseases like multiple sclerosis.
A study published in Environmental Health found a link between air pollution from traffic and an increased risk of developing dementia, Parkinson's disease, Alzheimer's disease, and multiple sclerosis. Living near green spaces appears to have protective effects against these neurological disorders.
Researchers at UMass Chan Medical School have developed a gene therapy approach that protects synaptic connections in the brain from damage in multiple sclerosis models. The study suggests that therapies targeting specific circuits of the brain could be effective in preserving vision and preventing neurodegenerative symptoms.
Researchers at Kessler Foundation identified specific brain regions associated with memory rehabilitation using the modified Story Memory Technique. Participants showed decreased brain activity in language network, default mode network, and executive control network, leading to improved learning and memory outcomes.
The cost of MS drugs increased from $453 million to $1.32 billion between 2011 and 2017, driven by prescription costs that doubled during this period.
Researchers identify Protease Activated Receptor 1 (PAR1) as a molecular switch that promotes myelin regeneration, potentially improving function in neurological disorders. The study's findings suggest new strategies for treating diseases of the central nervous system.
A clinical trial is testing an experimental stem cell treatment against the best available biologic therapies for severe forms of relapsing multiple sclerosis. The trial aims to determine whether autologous hematopoietic stem cell transplantation (AHSCT) is an effective and durable treatment option for people with severe relapsing MS w...
Researchers identified deficits in prospective memory as factors affecting performance of everyday life activities in individuals with multiple sclerosis. Time-based tasks showed poorer performance compared to event-based tasks, and were associated with executive function deficits and lower motor scores.
A working group of medical organizations analyzed 29 pivotal phase III trials for disease-modifying drugs in MS, finding that patient symptoms and quality of life were often not considered. They suggest improving studies by focusing on patient-reported outcomes and long-term treatment effects.
Researchers conducted a literature review to summarize outcomes in patients with MS who smoke cigarettes and are exposed to smoke. The study found associations between cigarette smoking and increased risk of MS relapses, disability, and mortality.
A study found that individuals with multiple sclerosis who struggle with money management have difficulty with executive functioning and low depressive symptomatology. This can lead to serious financial, legal, and psychological consequences. Understanding these underlying factors is crucial for identifying those at risk and providing ...
A new study by University of Wisconsin-Madison researchers found that changes in VEP latency can accurately reflect remyelination in multiple sclerosis patients, providing a potential outcome measure for evaluating new treatments.
Research finds gut protein Smad7 mobilizes immune cells, triggering inflammation in the central nervous system of MS patients. Analyzing intestinal tissue samples from MS patients confirms results, suggesting a potential therapeutic target for this debilitating disease.
Researchers at Karolinska Institutet developed a new method to separate between two types of herpes virus 6A and 6B, found that MS-patients carry the virus 6A to a greater extent than healthy individuals, and that HHV-6A may be contributing factor to multiple sclerosis development
A team of investigators from Brigham and Women's Hospital has identified a specific microRNA, miR-30d, that increases during peak disease in MS patients. Orally administering a synthetic version of the microRNA prevented disease in a preclinical mouse model.
A study found that MS drug prices are increasing due to profit-driven business models, with executives citing the US market as a key factor. The researchers noted that prices in the US continue to rise despite decreased production costs.
Researchers found associations between sensory difficulties, cognitive impairments, and disease severity in individuals with multiple sclerosis. Sensory processing deficits also affected functional performance of everyday life activities.
A study published in Science Translational Medicine founds that blocking the molecule ALCAM can delay the progression of multiple sclerosis. The disease causes symptoms such as fatigue, lack of coordination and vision problems in people like 20,000 Canadians with the disease.
Researchers used powerful imaging technology to discover a common indicator of brain inflammation in early-stage MS patients and its link to gray matter damage. The study found LME was present in nearly two-thirds of the patients, with significant correlations to lesions in gray matter regions.
A recent study published in Neurology reveals that individuals with multiple sclerosis (MS) who also suffer from depression are more likely to experience debilitating symptoms earlier than those without depression. The research highlights the need for early recognition and treatment of depressive symptoms in patients with MS.
The Center for BrainHealth has awarded five scientists with innovative research grants to study brain health and performance. These studies aim to improve understanding of brain disorders and develop new treatments, including biomarkers for dementia and multiple sclerosis.
A study at Johns Hopkins Medicine identified three complement system genes linked to MS-caused vision loss. The researchers found that patients with specific genetic changes in these genes were more likely to experience severe vision problems, opening up new avenues for precision medicine and potential treatments.
Researchers at TalTech have identified a new receptor, P2X4, in human eosinophils that plays a key role in the communication between the immune system and nervous system. The discovery has implications for understanding multiple sclerosis and cancerous lesions.
Dr. Bruce Alberts will receive the 2020 John Edward Porter Legacy Award for his commitment to scientific research and education. The award recognizes his efforts to promote science as inquiry and improve science education in primary and secondary schools.
A recent study found that risk factors for unemployment among individuals with multiple sclerosis (MS) differ by age group. Factors such as physical symptoms, psychological issues, and person-specific traits were identified as contributing to the high unemployment rate among MS patients, with younger and older adults experiencing diffe...
A new grant from the Consortium of Multiple Sclerosis Centers will allow researchers to investigate different types of exercise regimens in individuals with multiple sclerosis. The study aims to measure the effects of exercise on various aspects of MS-related symptoms, such as cognition, fatigue, and physical functioning.
Researchers at UVA School of Medicine found that oligodendrocyte progenitor cells, previously thought to be harmless, actively participate in the immune system's attacks on myelin in multiple sclerosis. This discovery offers new hope for finding a cure by promoting brain repair and targeting both aspects of the pathology.
Researchers identified a specific subgroup of helper T cells driving MS and found that targeting the CXCR6 protein prevented and reversed the disease in mouse models. Elevated levels of CXCR6-positive cells were also found in inflamed joints of patients with inflammatory autoimmune arthritis.
A new study has identified 233 genetic sites that contribute to multiple sclerosis (MS) susceptibility, highlighting the involvement of peripheral immune cells and microglia. The findings confirm earlier results and provide a rich perspective on the molecular events leading to MS.
Researchers found that neuropsychological tests have predictive value for everyday life activities in individuals with MS. However, non-cognitive variables and person-specific factors also play a crucial role in evaluating the impact of the disease on daily functioning.
A new tablet-based app offers a faster, easier, and more accurate way to assess the cognitive function of people with multiple sclerosis. The app, called iCAMS, reduced test time from about 23 minutes to 14 minutes while producing highly accurate results.